Advanced Filters
noise
Found 387 clinical trials
H Huaiwu Lu, M.D., Ph.D.

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live …

18 - 45 years of age Female Phase 2
F Fa'urinda R Prabu Nery, S1

Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management

This study compared the efficacy and safety of superior hypogastric plexus block and ganglion impar block procedures on the management of pelvic and perineal cancer pain in patients with cervical and endometrial cancer

18 years of age Female Phase N/A
Z Zheng Zeng, MD.

Spectral CT in Radiotherapy for Cervical Cancer

The purpose of this study was to explore the potential application of spectral CT for radiotherapy in cervical cancer.

18 years of age Female Phase N/A

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

This Phase II study is a clinical trial to evaluate the efficacy and safety of BL-B01D1 + pembrolizumab dual therapy with or without bevacizumab (BL-B01D1 + pembrolizumab ± bevacizumab) in patients with recurrent or metastatic cervical cancer and endometrial cancer.

18 - 75 years of age All Phase 2
S Supriya J Sastri, MD

Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study

Cervical cancer is the 4th most common cancer in women globally and the 2nd most common in India. In India, between 2018 and 2020, cervical cancer saw a surge of 26,985 from 2018 to 2020. The treatment for cervical cancer depends on the clinical stage. Treatment of early stage cervical …

18 - 75 years of age Female Phase N/A
T Tissana Prasartseree, MD

Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer

This study aims to evaluate a shorter course of postoperative pelvic radiotherapy in patients with cervical and endometrial cancer. The standard radiotherapy schedule usually requires many treatment sessions over several weeks, which can be burdensome for patients and may affect their ability to complete treatment. This study will compare a …

18 years of age All Phase N/A
L Lalicia Roman

GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries

The purpose of study is to compare the side effects of two different forms of radiation for endometrial and cervical cancer. If you decide to enroll in this study, you will be randomized to one of two treatment groups. This study will compare two standard of care treatments: "Conventional" pHoton …

18 years of age Female Phase 2
K Kasra Kolahdouzan, M.D.

Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer

Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the …

18 - 85 years of age Female Phase 2

Intra-lesional Tumor Boost for Bulky Cervical Cancer

The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment. The main questions it aims to answer are: Does the extra radiation boost effectively reduce the …

19 - 80 years of age Female Phase 2
H He Hai Xin

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.

18 - 75 years of age Female Phase 2

Simplify language using AI